Abstract:e16215 Background: Pancreatic cancer is one of the most fatal cancers worldwide. In addition to patients presenting later in the disease, limitations in current testing modalities pose a challenge to early diagnosis and treatment. Somatic mutations of the K-Ras gene have been suggested as a key driver of pancreatic carcinogenesis and thus proposed as a biomarker for diagnosis and therapy. Majority of these studies utilize tissue-based methods for analyzing K-Ras mutations. In recent years, liquid biopsy assay, in particular, analysis of cell-free DNA (cfDNA), has emerged as a promising noninvasive diagnostic approach in oncology, with the respect to the identification of minimal residual diseases, monitoring treatment response, detection recurrence and metastasis, and identification of chemo-resistance mechanisms. The application of digital PCR based plasma cfDNA K-Ras mutation assay in pancreatic cancer has not been reported. Methods: We included patients who underwent evaluation of a pancreatic lesion detected by conventional radiography (CT/MRI) and confirmed by endoscopic ultrasound (EUS) and biopsy. The biopsies from pancreatic tissues were formalin-fixed and paraffin-embedded (FFPE) for pathological diagnosis, and the total DNA was extracted from the FFPE slides. In addition, matched blood from the same patient was collected at the time of biopsy, and plasma cfDNA was extracted. Both DNA quality and concentration were evaluated. 4.0 ng of DNA was used for droplet digital PCR (ddPCR) analysis. K-Ras G12D, G12V, G12R, G12C, G12A, G12S, and G13D mutations were analyzed by multiplexed assay reagents. The sensitivity cut-off of the multiplexed K-Ras G12/G13 assay was 1.0%. Results: cfDNA could be detected in the initiation of pathological diagnosis. Among the twelve patients with pancreatic lesions, eight (67%) were pancreatic ductal adenocarcinoma (PDAC) (head (4), body (2), tail (2) of the pancreas), one was acute pancreatitis, one was a tail cyst and two were unspecified non-malignant lesions. All the eight PDAC (100%) FFPE tissues exhibited K-Ras G12/13 mutations (Scores: 4.2-41.5%), while none of the non-malignant lesions (0%) demonstrated K-Ras mutations. Interestingly, K-Ras mutations were detected from seven of the eight PDAC patient’s plasma cfDNA (87.5%) (Scores: 1.2-20.7%) while the plasma cfDNA from patients with non-malignant lesions did not show any positive K-Ras mutations. Conclusions: Digital PCR-based plasma cfDNA assay for K-Ras mutation is a promising tool for diagnosis of PDAC and is comparable to tissue-based assays. Larger prospective studies can substantiate this and explore their roles in the prediction and early detection of recurrence of PDAC.

A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer

Values of Mutations of K-ras Oncogene at Codon 12 in Detection of Pancreatic Cancer: 15-Year Experience

K-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysis.

Detection Of Kras Gene Mutations In Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy For Improving Pancreatic Cancer Diagnosis

Identification of K-ras Mutations in Pancreatic Juice in the Early Diagnosis of Pancreatic Cancer

K-Ras Mutation Detection in Liquid Biopsy and Tumor Tissue As Prognostic Biomarker in Patients with Pancreatic Cancer: a Systematic Review with Meta-Analysis

The Diagnostic Value of the K-ras Mutation Detection of Endoscopic Ultrasound-Guided Fine Needle Aspiration Specimen for Pancreatic Carcinoma

A Prospective Study of Detection of Pancreatic Carcinoma by Combined Plasma K -Ras Mutations and Serum CA19-9 Analysis

The study on the diagnostic and prognostic value of detecting K-ras mutations in plasma of patients with pancreatic cancer by a novel nano capture probe

[Significance of Detection of K-ras Gene Mutations and CA19-9 in Serum for Diagnosis of Pancreatic Carcinoma].

Combined detection of p16 aberrant methylation and K-ras gene mutation in pancreatic juice for diagnosis of pancreatic cancer

K-Ras Gene Mutation in the Diagnosis of Ultrasound Guided Fine-Needle Biopsy of Pancreatic Masses

A Novel Nanoprobe-Based Assay for Detecting K-ras Mutations in Plasma and Stool Samples from Patients with Pancreatic Cancer: Value in Diagnosis and Prognosis Evaluation

Detection Of K-Ras Gene Mutations In Feces By Magnetic Nanoprobe In Patients With Pancreatic Cancer: A Preliminary Study

[Experiment Study on the Diagnostic Value of Bile K-ras Gene Mutation Responsible to the Hepatic Metastasis of Pancreatic Cancer].

Digital PCR-based cell-free DNA K-Ras mutations analysis and clinical implication in pancreatic cancer.

Differential High-Resolution Melting Analysis for the Detection of K-ras Codons 12 and 13 Mutations in Pancreatic Cancer.

Detection of K-ras Gene Mutation at Codon 12 by Pancreatic Duct Brushing for Pancreatic Cancer.

The study of the relationship between clinical stage, or prognostic and kirsten rat sarcoma viral oncogene mutations of patients with pancreatic cancer detected by a nano probe

KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates with Clinical Stage in Pancreatic Cancer Patients

The Value of K-ras Gene Point Mutation in the Diagnosis of Pancreatic Adenocarcinoma